Guselkumab (Tremfya™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway. This article summarizes the milestones in the development of guselkumab leading to this first approval for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
CITATION STYLE
Markham, A. (2017). Guselkumab: First Global Approval. Drugs, 77(13), 1487–1492. https://doi.org/10.1007/s40265-017-0800-7
Mendeley helps you to discover research relevant for your work.